A phase IIa trial of the new tuberculosis vaccine, MVA85A, in HIV- and/or Mycobacterium tuberculosis-infected adults
about
Prime-boost approaches to tuberculosis vaccine developmentSerum indoleamine 2,3-dioxygenase activity is associated with reduced immunogenicity following vaccination with MVA85ANovel vaccination strategies against tuberculosis.The next 10 years for tuberculosis vaccines: do we have the right plans in place?Safety and reactogenicity of BCG revaccination with isoniazid pretreatment in TST positive adults.The influence of delivery vectors on HIV vaccine efficacyImmunogenicity and efficacy of a chimpanzee adenovirus-vectored Rift Valley fever vaccine in mice.Safety and immunogenicity of H1/IC31®, an adjuvanted TB subunit vaccine, in HIV-infected adults with CD4+ lymphocyte counts greater than 350 cells/mm3: a phase II, multi-centre, double-blind, randomized, placebo-controlled trial.Two doses of candidate TB vaccine MVA85A in antiretroviral therapy (ART) naïve subjects gives comparable immunogenicity to one dose in ART+ subjects.Vaccine against tuberculosis: what's new?Qualification of a whole blood intracellular cytokine staining assay to measure mycobacteria-specific CD4 and CD8 T cell immunity by flow cytometry.Novel GMO-Based Vaccines against Tuberculosis: State of the Art and Biosafety ConsiderationsNonclinical Development of BCG Replacement Vaccine Candidates.Lessons learnt from the first efficacy trial of a new infant tuberculosis vaccine since BCG.HIV-1 and the immune response to TB.Safety and immunogenicity of an FP9-vectored candidate tuberculosis vaccine (FP85A), alone and with candidate vaccine MVA85A in BCG-vaccinated healthy adults: a phase I clinical trial.Protection against tuberculosis with homologous or heterologous protein/vector vaccine approaches is not dependent on CD8+ T cellsHeterologous vaccination against human tuberculosis modulates antigen-specific CD4+ T-cell function.A randomized, controlled dose-finding Phase II study of the M72/AS01 candidate tuberculosis vaccine in healthy PPD-positive adults.T cell susceptibility to HIV influences outcome of opportunistic infections.Potential cost-effectiveness of a new infant tuberculosis vaccine in South Africa--implications for clinical trials: a decision analysis.The candidate TB vaccine, MVA85A, induces highly durable Th1 responses.Update in tuberculosis and nontuberculous mycobacterial disease 2012.Clinical applications of attenuated MVA poxvirus strain.Progress in the development of vaccines for hepatitis C virus infection.Trained immunity: a new avenue for tuberculosis vaccine development.A review of clinical models for the evaluation of human TB vaccines.Global Efforts in the Development of Vaccines for Tuberculosis: Requirements for Improved Vaccines Against Mycobacterium tuberculosis.MTBVAC from discovery to clinical trials in tuberculosis-endemic countries.Safety and immunogenicity of candidate vaccine M72/AS01E in adolescents in a TB endemic setting.How Can Elispot Add Information to Improve Knowledge on Tropical Diseases?Polyfunctional CD4+ T Cells As Targets for Tuberculosis VaccinationSafety and Immunogenicity of Newborn MVA85A Vaccination and Selective, Delayed Bacille Calmette-Guerin (BCG) for Infants of HIV Infected Mothers: A Phase 2 Randomized Controlled Trial.Recent developments in tuberculosis vaccines
P2860
Q27024526-D3EC2ED0-1F53-4BCA-A0B2-43B09911D61EQ28649845-6344B68B-CA80-440C-9E4B-90A421D4EAC8Q30363188-A1A476A6-A742-4B1E-A4D9-FBE9C812EE1BQ33659150-E43919C2-88FA-4661-9040-8889C7D7EDE2Q34055234-ADBF4A23-DA46-461E-870D-E5987695FDE3Q34077543-29758A0A-79A6-48C6-B7C8-1D42FB6C5C17Q34529382-5FC9C7C7-22E8-495A-835E-0AD4E4DCD3F4Q34663035-54604B9C-54E6-4669-BA53-120D1A7E2D16Q34806664-A86F8A8D-DB97-44D9-8533-4D9BB01B1A1CQ35101472-4BF6DCA1-4761-4473-B3D2-4199954896BBQ35117812-D5D4DB7C-4A30-4FF4-B2FE-7168D26BC110Q35826779-4115649A-9B93-462E-B106-4FA1DFF2BD16Q35890636-72FC0FD9-D7DC-4C36-B32B-70B9B144C0C8Q36715923-16301B18-B436-4813-833D-CF8CE0235A70Q36815449-800D2858-61D2-4B71-873B-FFD6340A0909Q36888036-5B213FF2-DFE0-4540-88E4-1CFF3659DD43Q37218080-0446E464-87DA-4AC7-AFBE-BA9AD8BE38E2Q37275906-AFCB2DB0-CBBE-48A9-812D-AA6B31F1D780Q37301506-1848390C-91B0-4D6E-82B9-40E01EDB67AEQ37382387-0E88D069-A862-4FFF-9912-7411C0408A95Q37483591-80CE473E-E869-4294-8FF5-61C5B1B46454Q37548692-81E09765-8E37-409D-8EFA-2D30A9983734Q38152788-A0DD6BF8-F93B-4A6F-817F-9E13438C8B0EQ38156198-94D735E3-1D7E-4A68-AEBE-E04F13904FF1Q38635596-03CA4616-1511-44B3-891F-4B390297B8BCQ38646341-6A5B3036-5F1F-4378-A87D-91C3C542490BQ38711772-2BECE5F3-E770-41C9-817B-273A9BDDD17FQ38907507-CC6299AF-9908-4678-9440-C9642A2E184BQ39266421-2635CE5B-E124-4A45-AB23-BFE2C457683FQ41162993-9AC6CD98-C1E0-4FBB-A1B8-CA9138ADA169Q41928044-4707872E-A5EA-4EDC-B452-C4AA5DB200ECQ42373425-F97D29DD-76D1-4404-B32C-17A40CE47DBEQ47613899-D09FF43A-6288-4FC6-AD90-B6F5C97E96E0Q58834925-987D7251-F48C-485F-9328-8BFB720F92AD
P2860
A phase IIa trial of the new tuberculosis vaccine, MVA85A, in HIV- and/or Mycobacterium tuberculosis-infected adults
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
A phase IIa trial of the new t ...... m tuberculosis-infected adults
@ast
A phase IIa trial of the new t ...... m tuberculosis-infected adults
@en
type
label
A phase IIa trial of the new t ...... m tuberculosis-infected adults
@ast
A phase IIa trial of the new t ...... m tuberculosis-infected adults
@en
prefLabel
A phase IIa trial of the new t ...... m tuberculosis-infected adults
@ast
A phase IIa trial of the new t ...... m tuberculosis-infected adults
@en
P2093
P2860
P50
P1476
A phase IIa trial of the new t ...... m tuberculosis-infected adults
@en
P2093
Alison Lawrie
Anthony Hawkridge
Ashley Veldsman
Blessing Kadira
E Jane Hughes
Erica Smit
Esme Janse van Rensburg
Hassan Mahomed
Hendrik Geldenhuys
Humphrey Mulenga
P2860
P304
P356
10.1164/RCCM.201108-1548OC
P407
P50
P577
2012-01-26T00:00:00Z